Skip to main content
Article thumbnail
Location of Repository

Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial

By S. Aslanyan, C.J. Weir, K.W. Muir and K.R. Lees

Abstract

<p><b>Background and Purpose:</b> A prespecified interaction analysis of the neutral Intravenous Magnesium Efficacy in Stroke (IMAGES) trial revealed significant benefit from magnesium (Mg) in patients with noncortical stroke. Post hoc analysis indicated that this effect was seen in lacunar clinical syndromes (LACS), interaction P=0.005. We have now examined whether this interaction could be explained by confounding baseline factors.</p>\ud \ud <p><b>Methods:</b> LACS was defined on the basis of neurological signs and did not include imaging. We investigated the interaction between baseline variables and Mg treatment on global outcome. We used logistic-regression models to test whether the Mg-LACS interaction remained significant after adjusting for stratification variables, sex, a novel stroke severity score, and baseline variables that had an interaction with treatment (P<0.1).</p>\ud \ud <p><b>Results:</b> The Mg (n=383) and placebo (n=382) groups of LACS patients were well matched on baseline factors. In addition to LACS, we found an interaction between beneficial Mg treatment effect and younger age (P=0.003), higher baseline diastolic blood pressure (P=0.02), higher mean blood pressure (P=0.02), and absence of ischemic heart disease (P=0.07). Even so, the adjusted Mg-LACS interaction remained significant (odds ratio [OR] 0.57; 95% CI, 0.39 to 0.83; P=0.003). In the LACS subgroup, Mg improved Barthel Index <95 (OR 0.73; 95% CI, 0.55 to 0.98), modified Rankin Scale >1 (OR 0.67; 95% CI, 0.50 to 0.91), and global outcome (OR 0.70; 95% CI, 0.53 to 0.92) but not Barthel Index <60 or mortality.</p>\ud \ud <p><b>Conclusions:</b> The positive treatment effect of Mg in LACS cannot be ascribed to general issues of severity, time to treatment, blood pressure, or other baseline factors; equally, this finding may be due to chance. A large trial of Mg treatment in LACS appears justified.</p&gt

Publisher: American Heart Association
Year: 2007
OAI identifier: oai:eprints.gla.ac.uk:19355
Provided by: Enlighten

Suggested articles

Citations

  1. (2006). Agreement between clinical syndrome classification and brain imaging in the Intravenous Magnesium Efficacy in Stroke (IMAGES) Trial. Cerebrovasc Dis.
  2. (1957). Cerebral vascular accidents in patients over the age of 60, II: prognosis. Scott Med J.
  3. Classical lacunar syndromes. In: Bogousslavsky doi
  4. Classification and natural history of clinically identifiable subtypes of cerebral infarction. doi
  5. (2006). Does the IMAGES stroke scale provide more information than a simple clinical classification? Cerebrovasc Dis.
  6. for the ECASS I Group. Identification of lacunar infarcts before thrombolysis in the ECASS I study. doi
  7. Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. doi
  8. Neuroprotection for acute stroke: making clinical trials work. doi
  9. New concepts in lacunar stroke etiology: the constellation of small-vessel arterial disease. Cerebrovasc Dis. doi
  10. Risk factors or early recurrence after ischemic stroke: the role of stroke syndrome and subtype. doi
  11. Strengthening acute stroke trials through optimal use of disability endpoints. doi
  12. The pathophysiology of anoxic injury in central nervous system white matter. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.